CA2096001A1 - Compositions of gastric acid-resistant microspheres containing salts of bile acid - Google Patents

Compositions of gastric acid-resistant microspheres containing salts of bile acid

Info

Publication number
CA2096001A1
CA2096001A1 CA002096001A CA2096001A CA2096001A1 CA 2096001 A1 CA2096001 A1 CA 2096001A1 CA 002096001 A CA002096001 A CA 002096001A CA 2096001 A CA2096001 A CA 2096001A CA 2096001 A1 CA2096001 A1 CA 2096001A1
Authority
CA
Canada
Prior art keywords
compositions
acid
containing salts
microspheres containing
gastric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002096001A
Other languages
French (fr)
Other versions
CA2096001C (en
Inventor
Tibor Sipos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Digestive Care Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2096001A1 publication Critical patent/CA2096001A1/en
Application granted granted Critical
Publication of CA2096001C publication Critical patent/CA2096001C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed are gastric acid-resistant polymer-coated ursodeoxycholate compositions, process for their preparations and methods of treating digestive disorders, impaired liver function, autoimmune diseases of the liver and biliary tract, prevention of colon cancer following cholecystectomy, cystic fibrosis, dissolving gallstones and regulating dietary cholesterol absorption by administering said compositions to a mammal in need of such treatment.
CA002096001A 1992-06-22 1993-05-11 Compositions of gastric acid-resistant microspheres containing salts of bile acid Expired - Fee Related CA2096001C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/902,578 US5234697A (en) 1992-06-22 1992-06-22 Compositions of gastric acid-resistant microspheres containing salts of bile acids
US07/902,578 1992-06-22

Publications (2)

Publication Number Publication Date
CA2096001A1 true CA2096001A1 (en) 1993-12-23
CA2096001C CA2096001C (en) 2005-05-03

Family

ID=25416053

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002096001A Expired - Fee Related CA2096001C (en) 1992-06-22 1993-05-11 Compositions of gastric acid-resistant microspheres containing salts of bile acid

Country Status (3)

Country Link
US (2) US5234697A (en)
AU (1) AU4132893A (en)
CA (1) CA2096001C (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5415872A (en) * 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5460812A (en) * 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
DE4239442C2 (en) * 1992-11-24 2001-09-13 Sebo Gmbh Use of an adsorbent material modified with polynuclear metal oxide hydroxides for the selective elimination of inorganic phosphate from protein-containing liquids
WO1995003056A1 (en) * 1993-07-19 1995-02-02 Tokyo Tanabe Company Limited Hepatitis c virus proliferation inhibitor
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
DE29717252U1 (en) * 1997-09-26 1998-02-19 Falk Pharma Gmbh Drug kit consisting of a budesonide-containing and an ursodeoxycholic acid-containing drug for the treatment of cholestatic liver diseases
DE19901692C2 (en) * 1999-01-18 2002-06-20 Gruenenthal Gmbh Process for the production of pellets containing up to 90% by weight of an active pharmaceutical ingredient
DE19906290A1 (en) * 1999-02-15 2000-08-17 Falk Pharma Gmbh Orally administered medicament for treating colon cancer comprises ursodesoxycholic acid in gastric fluid resistant coating to provide direct topical action at target site
DE19918325A1 (en) 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
AR034813A1 (en) * 2001-07-20 2004-03-17 Novartis Ag PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
SI2319804T1 (en) * 2006-12-14 2015-01-30 Novartis Ag Iron(III)-Carbohydrate based phosphate adsorbent
EP2367554A4 (en) 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
ES2552657T3 (en) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibitors of the recycling of bile acids and satiogens for the treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
FR2981572B1 (en) * 2011-10-21 2018-01-19 Inopharm Limited PHARMACEUTICAL COMPOSITIONS OF URSODESOXYCHOLIC ACID

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004893A (en) * 1959-10-21 1961-10-17 Richardson Merrell Inc Enteric coated trypsin and chymotrypsin anti-inflammatory compositions
US3064622A (en) * 1960-06-20 1962-11-20 Xerox Corp Immersion development
GB1362365A (en) * 1970-07-28 1974-08-07 Novo Terapeutisk Labor As Production of enzyme preparations
USRE30910E (en) * 1971-03-19 1982-04-20 Intellectual Property Development Corporation Reducing cholesterol levels
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE2923279B1 (en) * 1979-06-08 1980-11-20 Kali Chemie Pharma Gmbh Process for the production of pancreatin pellets
DE3572440D1 (en) * 1984-06-19 1989-09-28 Basf Ag Gastro-resistant cylindrical pancreatine-microtablets
JPS62175497A (en) * 1986-01-28 1987-08-01 Wakunaga Pharmaceut Co Ltd Bile acid derivative and production thereof
CH674369A5 (en) * 1986-11-26 1990-05-31 Jago Res Ag
EP0321527B1 (en) * 1987-07-01 1992-08-12 Ici Australia Operations Proprietary Limited Water dispersible granules
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof

Also Published As

Publication number Publication date
US5352460A (en) 1994-10-04
US5234697A (en) 1993-08-10
CA2096001C (en) 2005-05-03
AU4132893A (en) 1993-12-23

Similar Documents

Publication Publication Date Title
CA2096003A1 (en) Compositions of Gastric Acid-Resistant Microspheres Containing Buffered Bile Acids
CA2096002A1 (en) Compositions of Digestive Enzymes and Salts of Bile Acids and Process of Preparation Thereof
CA2096001A1 (en) Compositions of gastric acid-resistant microspheres containing salts of bile acid
WO1997049736A3 (en) Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
CA2228389A1 (en) High buffer-containing enteric coated digestive enzyme bile-acid compositions and method of treating digestive disorders therewith
CA2117891A1 (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
AU6948994A (en) Iron-binding polymers for oral administration
NO940035L (en)
CA2325933A1 (en) Fatty acid derivatives of bile acids and bile acid derivatives
AU6969194A (en) Compositions for use in the regulation of subnormal ph values in the intestinal tract and for treatment of bowel diseases
CA2065809A1 (en) Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acids
AU560251B2 (en) Pharmaceutical compositions of mopidamol
HUT74180A (en) Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation pharmaceutical compositions containing them and process for producing them
CA2059865A1 (en) Pharmaceutical Compositions Containing Orally Absorbable Glycosaminoglycans
IE821453L (en) Oral dipyridamole preparations
CA2065773A1 (en) Gastroresistant pharmaceutical formulations for oral administration containing bile acids
CA2272711A1 (en) Method for treating renal failure
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
FR2469925A1 (en) USE OF B-CYCLODEXTRIN AS ANTI-ACNE AGENT
CA2238040A1 (en) Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders and other applications
CA2266608A1 (en) Combination composition in the form of nutritional supplement or pharmaceutical composition for the prevention and therapeutical treatment of degenerative or inflammatory articular disorders
IL117882A0 (en) Dermatological preparation and method of treating actinic keratoses
CA2067863A1 (en) Medicine for the treatment of illnesses of the respiratory organs
CA2140361A1 (en) Composition and methods for decreasing muscle breakdown
CA2113916A1 (en) 6-Chloro-5-Fluoro-3-(2-Thenoyl)-2-Oxindole-1-Carboxamide as an Analgesic and Anti-Inflammatory Agent

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20100511